Corewire actuated delivery system with fixed distal stent-carrying extension

Information

  • Patent Grant
  • 7651521
  • Patent Number
    7,651,521
  • Date Filed
    Thursday, November 18, 2004
    19 years ago
  • Date Issued
    Tuesday, January 26, 2010
    14 years ago
Abstract
Medical device and methods for delivery or implantation of prostheses within hollow body organs and vessels or other luminal anatomy are disclosed. The subject technologies may be used in the treatment of atherosclerosis in stenting procedures. For such purposes, a self-expanding stent is deployed in connection with an angioplasty procedure with a corewire actuated delivery system having a fixed distal stent-carrying extension. Withdrawal of the corewire retracts a restraint freeing the stent from a collapsed state, whereupon the stent assumes an expanded configuration set in apposition to the interior surface of a vessel lumen in order to help maintain the vessel open.
Description
FIELD OF THE INVENTION

The present invention relates generally to medical device and methods. More particularly, it relates to delivery systems for implanting prostheses within hollow body organs and vessels or other luminal anatomy.


BACKGROUND OF THE INVENTION

Implants such as stents and occlusive coils have been used in patients for a wide variety of reasons. One of the most common “stenting” procedures is carried out in connection with the treatment of atherosclerosis, a disease which results in a narrowing and stenosis of body lumens, such as the coronary arteries. At the site of the narrowing (i.e., the site of a lesion) a balloon is typically dilatated in an angioplasty procedure to open the vessel. A stent is set in apposition to the interior surface of the lumen in order to help maintain an open passageway. This result may be effected by means of scaffolding support alone or by virtue of the presence of one or more drugs carried by the stent aiding in the prevention of restenosis.


Various stent designs have been developed and used clinically, but self-expandable and balloon-expandable stent systems and their related deployment techniques are now predominant. Examples of self-expandable stents currently in use are the Magic WALLSTENT® stents and Radius stents (Boston Scientific). A commonly used balloon-expandable stent is the Cypher® stent (Cordis Corporation). Additional self-expanding stent background is presented in: “An Overview of Superelastic Stent Design,” Min. Invas Ther & Allied Technol 2002: 9(3/4) 235-246, “A Survey of Stent Designs,” Min. Invas Ther & Allied Technol 2002: 11(4) 137-147, and “Coronary Artery Stents: Design and Biologic Considerations,” Cardiology Special Edition, 2003: 9(2) 9-14, “Clinical and Angiographic Efficacy of a Self-Expanding Stent” Am Heart J 2003: 145(5) 868-874.


Because self-expanding prosthetic devices need not be set over a balloon (as with balloon-expandable designs), self-expanding stent delivery systems can be designed to a relatively smaller outer diameter than their balloon-expandable counterparts. As such, self-expanding stents may be better suited to reach the smallest vasculature or achieve access in more difficult cases.


To realize such benefits, however, there continues to be a need in developing improved delivery systems. Problems encountered with known systems include drawbacks ranging from failure to provide means to enable precise placement of the subject prosthetic, to a lack of space efficiency in delivery system design. Poor placement hampers stent efficacy. Space inefficiency in system design prohibits scaling the systems to sizes as small as necessary to enable difficult access or small-vessel procedures (i.e., in tortuous vasculature or vessels having a diameter less than 3 mm, even less than 2 mm).


One known stent delivery system comprises a simple sheath set over a pusher in abutment with a stent. An example of such a system is disclosed in U.S. Pat. No. 4,580,568. Though elegant in design, the system fails to offer desired functional characteristics. Particularly, such a system is prone to misuse when a physician who in not intimately familiar with the hardware retracts or pushes the wrong one of the stent-abutting member or the sheath in an effort to free the stent. Dedicated handle systems have been developed to address this problem. Examples are provide in WO 99/04728, WO 00/18330, WO 98/23241, EP-A-747021, DE-A-44 20142 and U.S. Pat. No. 5,433,723.


Even when not misused, simple sheath system present issues with precise stent placement stemming from the fact that the sheath cannot be locked-down at the proximal end of an access catheter (e.g., at a hemostatic valve) while deploying the stent. As a result, it is difficult to prevent inadvertent axial movement of the stent. Because the sheath cannot be held onto, stent deployment requires that a user hold the pusher member (or handle attached thereto) steady while withdrawing the sheath in order to avoid pushing the stent forward within the vessel thereby complicating stent placement or producing “skid-marks” and even vessel perforation.


The system described in U.S. Pat. No. 5,534,007 assigned to SciMed Life Systems, Inc. offers an alternative to a simple-sheath type system for deploying self-expandable stents. The proximal end of the noted system can be locked-down to possibly aid in reducing stent movement during restraint withdrawal. Yet, the system requires a collapsible, bellows-type sheath portioned between the stationary proximal sleeve and the moveable distal restraint. Furthermore, the system is deployed over a guidewire. Because of the large “over-the-guidewire size” and increasing size of the device resulting by compression of the bellows, the device is not believed capable of being able to access or be withdrawn from the smallest and/or most tortuous anatomy.


Accordingly, there exists a need for a system to better enable precise stent placement than a simple sheath system, but offering improved space efficiency over other known self-expanding stent delivery systems such as that in the '007 patent. Those with skill in the art may also appreciate further advantages or benefits of the invention.


SUMMARY OF THE INVENTION

The present invention offers a highly-advantageous system for precise stent placement, allowing a user to conveniently lock-down the system if desired and deliver a stent thus set in place. The system includes a stent and a delivery guide for carrying the stent to a treatment site and releasing the stent at that point. To facilitate the lock-down function, the delivery guide is configured such that it is actuated by a member interior to an outer sleeve onto which the hemostatic valve of a catheter (e.g., a microcatheter or balloon catheter) can be collapsed. The inner member may be a core member (i.e., filling the center of or being coaxial with the sleeve) or one of a number of inner members.


By actuating the interior member (e.g., by withdrawing the same or by a physical shortening, such as by a heat-activated shape memory plastic or alloy wire), a restraint holding a stent over a separate, distal extension wire is moved off of the stent it holds in a collapsed configuration. Accordingly, simple withdrawal of the inner member will deploy the stent. Yet, a more user-friendly handle could be provided. In any case, the inventive system preferably offers a simple and space efficient proximal shaft that consists of an outer tubular sleeve member and a corewire therein. Such a system is easily fit to a manipulator and/or directly manipulated by a surgeon.


In the present invention, an implant delivery system is provided in which a stent or other radially expandable implant is held in a collapsed position over a wire extending from a sleeve receiving the core member, where the extension wire preferably includes an atraumatic tip. As opposed to a system in which a simple full-length sheath is employed, the restraint only covers the implant or the implant and some distal portion of the delivery device proximal to the stent. The length of the restraint may be selected according to the teachings of U.S. patent application Ser. No. 10/792,684, entitled “Sliding Restraint Stent Delivery Systems” filed on even date herewith and incorporated by reference in its entirety.


The stent or other such implant as may be employed is preferably self-expanding upon release of the restraint. Thus, full or complete placement of the stent can be achieved upon its release from the delivery device.


Minimization of delivery device crossing profile and providing internal actuation of a device with a fixed distal tip is accomplished by a cooperative relationship between the inner and outer members of the device in which one or more bridge segments associated with the restraint provides a “cross-over” from a system outer diameter (that of the restraint located exterior of the stent) to a diameter within the sleeve (with attachment to the inner/core member).


The bridge section or segment is sized to allow retracting the restraint fully off of the stent without the sleeve interfering with simple axial movement of the restraint. The bridge may be sized so that a distal end of the sleeve stops restraint withdrawal upon release of the stent. Alternatively, the system may be configured to allow further withdrawal of the restraint.


The bridge segment may be provided in any of a number of manners. It may be a separate element attached to both the restraint and the inner/core member. Alternatively it may be an integral extension of the restraint, extending distally for connection to the inner member of the delivery system. Still further, the bridging element may be an extension from or an extension of the inner member of the device. Where the inner member is a “corewire”, the extension will likely neck-down or be offset to accomplish the bridge's cross-over or pass-through function.


One-sided, two-sided or three-sided bridge and sleeve/extension member connection approaches are contemplated as well. A one-sided approach may provided for the smallest possible overall delivery guide dimensions. Yet, multiple bridge member (even exceeding three) approaches may offer advantages in terms of balancing actuation loads and providing consistent flexibility performance. Another approach to achieve such balancing uses a single member, where that member is a tube or other hollow structure surrounding a structurally significant portion of the extension member.


As for the connection between the stent-carrying extension and proximal sleeve, a non-exhaustive set of options are detailed in the figures below. Alternative approaches may be employed in producing systems according to the present invention. In the broadest sense of the invention, the “connection” between the stent-carrying extension portion of the device and the proximal sleeve is intended to be generic. For instance, it may be in the form of a transition between differently shaped portions of a unitary piece of material. That is to say, the extension member/wire and sleeve members may be integral. Still, they will have a “connection” as intended herein between them.


The connection between the extension member carrying the stent and the sleeve may be made at the distal end of the sleeve. Alternatively, the connection may be set at a distal portion of the sleeve that is proximal to its end. In which case, the bridge sections and restraint length are set so as to cover, conceal or overlay the bridge sections within the sleeve.


Of course, the sleeve portion distal of the connection may be in the form of another tubular member attached at a proximal sleeve section. This approach may be desired for reason of using a thinner walled polymer distal sleeve section overlaying the bridge section(s) and even part of the restraint, while employing a metal hypotube for the proximal sleeve section where torquability and pushability requirements predominate.


A sleeve covering the bridge portion(s) can be used to help maintain alignment of components during navigation of anatomy. Indeed, if sufficiently robust, a distal sleeve section covering or a protective coil surrounding or overriding at least a portion of the extension member and bridge segment(s) can avoid a “cord effect” of the bridge(s) separating from alignment with the extension member upon system actuation to release a stent.


Other means of maintaining alignment of features are provided in other variations of the invention. In the variation of the invention noted above, the bridge segment is provided by a tubular member. By virtue of its geometry alone, it remains centered about the extension wire upon which it rides.


In another variation of the invention especially adapted to maintain element alignment, the bridge segment is optionally an extension of the core wire crossing from the inside of the sleeve to outside of it to the restraint. The bridge member may be tapered, smaller in diameter than the core wire or substantially the same in diameter. As in the variation of the invention above, in this variation, the hollow geometry of one of the system components ensures the members stay together during navigation and actuation irrespective of conditions.


Where the extension from the sleeve includes a tubular member, it also includes a wire extending from the distal end of the tubular extension member. The stent is then carried upon the reduced diameter wire extension. With the stent carried upon such a relatively small diameter body, the maximum system diameter can be minimized.


The present invention also includes a variation in which the bridge segment is nothing more than a direct connection (such as at least one pin, bent-over section of the core wire, a glue or solder joint, etc.) between the core member and the restraint. In this variation of the invention, for example, it may be the case that no tubular extension member is provided, but that instead the distal end of the sleeve is slotted. The extension member will then simply take the form of a wire connected distal to the slotted region through which the bride section slides to withdraw the restraint. Other variations are possible combining various aspects of the structures described above.


In any case, a stent stop or blocker surface is generally provided to abut the stent to hold it stationary within or relative to the delivery device upon withdrawal of the restraint. This surface may be provided in connection with the sleeve and/or the extension section. The stent stop or blocker may simply be provided by a distal portion of the proximal outer member/sleeve. Alternatively, the blocker may be in the form of a ground-in shoulder section or a ring or band, etc. connected to the extension member. Again, other possibilities exist as well, including forming the member of a radiopaque material or providing multiple interface or blocker surface features formed in the extension member under the stent. Such approaches in providing stent stop or blocker surface(s) are known in the art as described in U.S. Pat. Nos. 4,768,507; 5,484,444 and 6,302,893 as are releasable stent-holding adhesive surfaces as described in U.S. Pat. No. 5,026,377, and polymers in which to embed or grip a stent as described in U.S. Pat. Nos. 6,042,589 and 6,607,551—each patent incorporated by reference herein for its disclosure of such stent-stabilizing features.


The form of the restraint is also highly variable. In a most basic variation, it is a simple tubular member. When this form of restraint is slid axially off of the stent, the device will experience no change in its distal diameter. However, in another variation of the invention, the restraint may be adapted to collapse radially. A full discussion of such diameter adaptive restraint technology (DART™) systems is provided in U.S. patent application Ser. No. 10/792,657, entitled “Stent Delivery System with Diameter Adaptive Restraint,” filed on Mar. 2, 2004 and incorporated by reference herein in its entirety. Still further, the restraint may comprise one or more members wrapped or otherwise disposed about the stent. In such a multi-member restraint approach, the portions may be interconnected, interwoven or separate from one another.


Delivery systems and guides according to the present invention are amenable to scaling to sizes not previously achieved. Consequently, the systems may be used in lieu of a guidewire, such as in a “guidewireless” delivery approach. Still further, rather than providing an “over-the-wire” delivery system as referenced above, the present systems may be regarded as “on-the-wire” delivery systems, since—in effect—delivery is accomplished by a system in which the stent is carried by a delivery guide occupying a catheter lumen that would commonly otherwise be used to accommodate a guidewire.


Whether used in such a manner or otherwise (such as by configuring the subject systems for treating larger peripheral vessels), the present invention includes systems comprising any combination of the features described herein. Methodology described in association with the devices disclosed also forms part of the invention. Such methodology may include that associated with completing an angioplasty, bridging an aneurysm, deploying radially-expandable anchors for pacing leads or an embolic filter, or placement of a prosthesis within neurovasculature, an organ selected from the kidney and liver, within reproductive anatomy such as selected vasdeferens and fallopian tubes or other applications.


DEFINITIONS

The term “stent” as used herein refers to any coronary artery stent, other vascular prosthesis, or other radially expanding or expandable prosthesis or scaffold-type implant suitable for the noted treatments or otherwise. Exemplary structures include wire mesh or lattice patterns and coils, though others may be employed in the present invention.


A “self expanding” stent is a scaffold-type structure (serving any of a number of purposes) that expands by its own action from a reduced-diameter configuration to an increased-diameter configuration. The “diameter” need not be circular—it may be of any open configuration. Self-expanding materials may be so by virtue of simple elastic behavior, superelastic behavior, a shape memory effect (i.e., heat-activated transformation from martinsite to austenite) or some other manner. Since the stents will remain in the subject's body, the material should be biocompatible or at least be amenable to biocompatible coating. As such, suitable self expanding stent materials for use in the subject invention include Nickel-Titanium (i.e., NiTi) alloy (e.g., NITINOL) and various other alloys or polymers.


A “wire” as used herein generally comprises a common metallic member. However, the wire may be coated or covered by a polymeric material (e.g., with a lubricious material such as TEFLON®, i.e. PolyTetraFlouroEthelyne—PTFE) or otherwise. Still further, the “wire” may be a hybrid structure with metal and a polymeric material (e.g. Vectran™, Spectra™, Nylon, etc.) or composite material (e.g., carbon fiber in a polymer matrix). The wire may be a filament, bundle of filaments, cable, ribbon or in some other form. It is generally not hollow.


A “core” wire as referred to herein is a member internal to an outer member, such as a tubular member. As a core wire, the member, fills or at least substantially fills all of the interior space of the tubular member.


A “hypotube” or “hypotubing” as referred to herein means small diameter tubing in the size range discussed below, generally with a thin wall. The hypotube may specifically be hypodermic needle tubing. Alternatively, it may be wound or braided cable tubing, such as provided by Asahi Intec Co., Ltd or otherwise. As with the “wire” discussed above, the material defining the hypotube may be metallic, polymeric or a hybrid of metallic and polymeric or composite material.


A “sleeve” as referred to herein may be made of such hypotubing or otherwise. The sleeve may be a tubular member, or it may have longitudinal opening(s). It is an outer member, able to slidingly receive and hold at least a portion of an inner member.


An “atraumatic tip” may comprise a plurality of spring coils attached to a tapered wire section. At a distal end the coils typically terminate with a bulb or ball that is often made of solder. In such a construction, the coils and/or solder are often platinum alloy or another radiopaque material. The coils may also be platinum, or be of another material. In the present invention, the wire section to which the coils are attached may be tapered, but need not be tapered. In addition, alternate structures are possible. For instance, molding or dip-coating with a polymer may be employed. In one example, the atraumatic tip may comprise a molded tantalum-loaded 35 durometer Pebax™ tip. However constructed, the atraumatic tip may be straight or curved, the latter configuration possibly assisting in directing or steering the delivery guide to a desired intravascular location.


To “connect” or to have or make a “connection” between parts refers to fusing, bonding, welding (by resistance, laser, chemically, ultrasonically, etc), gluing, pinning, crimping, clamping or otherwise mechanically or physically joining, attaching or holding components together (permanently or temporarily).





BRIEF DESCRIPTION OF THE DRAWINGS

Each of the figures diagrammatically illustrates aspects of the invention. Of these:



FIG. 1 shows a heart in which its vessels may be the subject of one or more angioplasty and stenting procedures;



FIG. 2 shows an expanded stent cut pattern as may be used in producing a stent for use in the present invention;



FIGS. 3A-3L illustrate stent deployment methodology to be carried out with the subject delivery guide member;



FIG. 4 provides an overview of the inventive system;



FIGS. 5A-5C provide detailed views of a first variation of the present invention;



FIGS. 6A-6C provide detailed views of a second variation of present invention;



FIG. 7 provides detailed views of an alternative restraint approach that may be employed in the present invention;



FIG. 8A is a side view of yet another restraint approach as may be employed in the invention; FIG. 8B is a side-sectional view of the structure shown in FIG. 8A;



FIG. 9 is a side view of a variation of the invention related to that shown in FIGS. 5A-5C;



FIG. 10 is a side view of a variation of the invention related to that shown in FIGS. 6A-6C;



FIGS. 11A and 11B are cross-sectional side views of successive distal portions of another variation of the present invention;



FIGS. 12A-12C are cross-sectional views of the variation of the invention shown in FIGS. 11A and 11B, taken along lines C-C, D-D and E-E, respectively;



FIG. 13 is a cross-sectional side view of another variation of the present invention;



FIGS. 14A-14C are cross-sectional views of the variation of the invention shown in FIG. 13, taken along lines B-B, C-C and D-D, respectively;



FIG. 15 is a cross-sectional side view of still another variation of the invention; and



FIGS. 16A and 16B are cross-sectional views of the variation of the invention shown in FIG. 15, taken along lines B-B and C-C, respectively.





Variation of the invention from the embodiments pictured is, of course, contemplated.


DETAILED DESCRIPTION OF THE INVENTION

Before the present invention is described in detail, it is to be understood that this invention is not limited to particular variations set forth and may, of course, vary. Various changes may be made to the invention described and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process act(s) or step(s), to the objective(s), spirit or scope of the present invention. All such modifications are intended to be within the scope of the claims made herein.


Methods recited herein may be carried out in any order of the recited events which is logically possible, as well as the recited order of events. Furthermore, where a range of values is provided, it is understood that every intervening value, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. Also, it is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein.


All existing subject matter mentioned herein (e.g., publications, patents, patent applications and hardware) is incorporated by reference herein in its entirety except insofar as the subject matter may conflict with that of the present invention (in which case what is present herein shall prevail). The referenced items are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such material by virtue of prior invention.


Reference to a singular item, includes the possibility that there are plural of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “and,” “said” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation. Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.


Turning now to FIG. 1, it shows a heart 2 in which its vessels may be the subject of one or more angioplasty and/or stenting procedures. To date, however, significant difficulty or impossibility is confronted in reaching smaller coronary arteries 4. If a stent and a delivery system could be provided for accessing such small vessels and other difficult anatomy, an additional 20 to 25% coronary percutaneous procedures could be performed with such a system. Such a potential offers opportunity for huge gains in human healthcare and a concomitant market opportunity in the realm of roughly $1 billion U.S. dollars—with the further benefit of avoiding loss of income and productivity of those treated.


Features of the present invention are uniquely suited for a system able to reach small vessels (though use of the subject systems is not limited to such a setting.) By “small” coronary vessels, it is meant vessels having an inside diameter between about 1.5 or 2 and about 3 mm in diameter. These vessels include, but are not limited to, the Posterior Descending Artery (PDA), Obtuse Marginal (OM) and small diagonals. Conditions such as diffuse stenosis and diabetes produce conditions that represent other access and delivery challenges which can be addressed with a delivery system according to the present invention. Other extended treatment areas addressable with the subject systems include vessel bifurcations, chronic total occlusions (CTOs), and prevention procedures (such as in stenting vulnerable plaque).


Assuming a means of delivering one or more appropriately-sized stents, it may be preferred to use a drug eluting stent in such an application to aid in preventing restenosis. However, bare-metal stents may be employed in the present invention. The present invention is advantageously employed with self-expanding stents. However, the teachings herein may be adapted for application in the context of balloon-expandable stents.


In any case, features of the present invention are provided in order to hold an implant (e.g., a stent) to be delivered in an access or deployment configuration, after which, the implant assumes its deployed or expanded configuration. Hold-down features may restrain a stent under compressive forces, whereupon release, the stent “springs” open. Alternatively, the stent (or other implant) may simply be secured to the delivery member, where some other mechanism is used to open the stent (e.g., ceasing a flow of chilled saline, thereby allowing a shape memory devices (e.g., NiTi) to warm in order that a material phase change from martinsite to austenite will cause the stent to open).


While some might argue that the particular role and optimal usage of self expanding stents has yet to be defined, they offer an inherent advantage over balloon expandable stents. The latter type of devices produce “skid mark” trauma (at least when delivered uncovered upon a balloon) and are associated with a higher risk of end dissection or barotraumas caused at least in part by high balloon pressures and related forces when deforming a balloon-expandable stent for deployment.


Yet, with an appropriate deployment system, self-expanding stents may offer one or more of the following advantages over balloon-expandable models: 1) greater accessibility to distal, tortuous and small vessel anatomy—by virtue of decreasing crossing diameter and increasing compliance relative to a system requiring a deployment balloon, 2) sequentially controlled or “gentle” device deployment, 3) use with low balloon pre-dilatation (if desirable) to reduce barotraumas, 4) strut thickness reduction in some cases reducing the amount of “foreign body” material in a vessel or other body conduit, 5) opportunity to treat neurovasculature—due to smaller crossing diameters and/or gentle delivery options, 6) the ability to easily scale-up a successful treatment system to treat larger vessels or vice versa, 7) a decrease in system complexity, offering potential advantages both in terms of reliability and system cost, 8) reducing the effects of intimal hyperplasia, and 9) conforming to tapering anatomy—without imparting complimentary geometry to the stent (though this option exists as well).


At least some of these noted advantages may be realized using a stent 10 as shown in FIG. 2 in connection with the subject deployment system described in further detail below. Naturally, other stent configurations might be used instead. However, the one pictured is well suited for use in small vessels. It may be collapsed to an outer diameter of about 0.018 inch (0.46 mm), or even smaller to about 0.014 inch (0.36 mm)—including the restraint/joint used—and expand to a size (fully unrestrained) between about 1.5 mm (0.059 inch) or 2 mm (0.079 inch) or 3 mm (0.12 inch) and about 3.5 mm (0.14 inch).


In use, the stent will be sized so that it is not fully expanded when fully deployed against the wall of a vessel in order that it will provide a measure of radial force thereto. The force will secure the stent and offer potential benefits in reducing intimal hyperplasia and vessel collapse or even pinning dissected tissue in apposition.


The stent employed in connection with the subject delivery system preferably comprises NiTi that is superelastic at room temperature and above. Also, it is preferably electropolished. The stent may be a drug eluting stent (DES). Such drug can be directly applied to the stent surface(s), or introduced into an appropriate matrix.


In a 0.014 inch delivery system (one in which the maximum nominal outer diameter of the stent/coating and guide member/restraint have a diameter that does not exceed 0.014 inch), the thickness of the NiTi is about 0.0025 inch (0.64 mm) for a stent adapted to expand to 3.5 mm. Such a stent is designed for use in a roughly 3 mm vessel or other body conduit, thereby providing the desired radial force in the manner noted above. Further information regarding radial force parameters in coronary stents may be noted in the article, “Radial Force of Coronary Stents: A Comparative Analysis,” Catheterization and Cardiovascular Interventions 46: 380-391 (1999), incorporated by reference herein in its entirety.


As for the stent that may be employed, an optional expanded stent cut pattern 10 is shown in FIG. 2. In one manner of production, the stent is laser (or Electrical Discharge Machining, i.e., EDM) cut from round NiTi tubing, with the flattened-out pattern shown wrapping around the tube as indicated by dashed lines. In such a procedure, the stent is preferably cut in its fully-expanded shape. By initially producing the stent to full size, the approach allows cutting finer details in comparison to simply cutting a smaller tube with slits and then heat-expanding/annealing it into its final (working) diameter. Avoiding post-cutting heat forming also reduces production cost.


Regarding the finer details of the subject stent, necked down bridge or junction sections 12 are provided between adjacent struts 14, wherein the struts define a lattice of closed cells 16. The ends 18 of the cells are preferably rounded-off so as to be atraumatic. To increase stent conformability to tortuous anatomy, the bridge sections can be strategically separated or opened as indicated by broken line. To facilitate such tuning of the stent, the bridge sections are sufficiently long so that fully rounded ends 18 may be formed internally to the lattice just as shown on the outside of the stent if the connection(s) is/are severed to separate adjacent cells 16.


The advantage of the double-concave profile of each strut bridge or junction section 12 is that it reduces material width (relative to what would otherwise be presented by a parallel side profile) to improve trackability and conformability of the stent within the subject anatomy while still maintaining the option for separating/breaking the cells apart.


Further optional features of stent 10 are employed in the cell end regions 18 of the design. Specifically, strut ends 20 increase in width relative to medial strut portions 22. Such a configuration results in a majority of bending (during collapse of the stent) occurring along the length of the struts rather than at the corners of the cells. Longer struts to allow for lower stresses within the stent (and, hence, possibility for higher compression ratios). Shorter struts allow for greater radial force (and concomitant resistance to a radially applied load) upon deployment.


In order to provide a stent that collapses as much as possible (to solid or near-solid structure, such as shown in the fully-loaded systems of the figures) accommodation is made for the stiffer strut ends 20 provided in the design shown in FIG. 2. Namely, the gap 24 between the strut ends 22 is set at a smaller angle as if the stent were already partially collapsed in that area. Thus, the smaller amount of angular deflection that occurs at ends 20 will bring the sections parallel (or nearly so) when the strut medial portions 22 are so-arranged. Radiused sections 26 provide a transition from a medial strut angle α (ranging from about 85 degrees to about 60 degrees) to an end strut angle β (ranging from about 30 to about 0 degrees) at the strut junctions and/or extensions therefrom.


In addition, it is noted that gap 24 and angle β may actually be configured to completely close prior to fully collapsing angle α. The stent shown is not so-configured. Still, the value of doing so would be to limit the strains (and hence, stresses) at the strut ends 22 and cell end regions 18 by providing a physical stop to prevent further strain. Alternative, advantageous stent designs that may be used in connection with the present invention are presented in U.S. Provisional Patent Application Ser. No. 60/619,437, entitled, “Small Vessel Stent Designs”, filed Oct. 14, 2004 and incorporated herein by reference in its entirety.


By utilizing any of these designs, very high compression ratios of the stent may be achieved. Compression ratios (from a fully expanded outside diameter to compressed outside diameter—expressed in those terms used by physicians) of as much as 3.5 mm: 0.014 inch (about 10×) are possible—with or without a drug coating and/or restraint used. Compression ratios of 3.0 mm:0.014 inch (about 8.5×), 3.5 mm:0.018 inch (about 7.5×), 3.0 mm:0.018 inch (about 6.5×), 2.5 mm:0.014 inch (about 7×), 2.5 mm:0.018 inch (about 5.5×), 2.0 mm:0.014 inch (about 5.5×), 2.0 mm:0.018 inch (about 4.5×) offer utility not heretofore possible with existing systems as well.


These selected sizings (and expansion ratios) correspond to treating 1.5 to 3.0 mm vessels by way of delivery systems adapted to pass through existing balloon catheter and microcatheter guidewire lumen. In other words, the 0.014 inch and 0.018 inch systems are designed to corresponding common guidewire sizes. The system may also be scaled to other common guidewire sizes (e.g., 0.22 inch/0.56 mm or 0.025 inch/0.64 mm) while offering advantages over known systems.


While designing the delivery systems to have a crossing profile corresponding to common guidewire sizes, especially for full-custom systems, intermediate sizes may be employed. Still further, it is contemplated that the system sizing may be set to correspond to French (FR) sizing. In that case, system sizes contemplated range at least from 1 to 1.5 FR, whereas the smallest know balloon-expandable stent delivery systems are in the size range of about 3 to about 4 FR.


At least when produced at the smallest sizes (whether in a even/standard guidewire or FR size, or otherwise), the system enables a substantially new mode of stent deployment in which delivery is achieved through an angioplasty balloon catheter or small microcatheter lumen. Further discussion and details of “through the lumen” delivery is presented in the above-referenced “Balloon Catheter Lumen Based Stent Delivery Systems” patent application.


In “small vessel” cases or applications (where the vessel to be treated has a diameter up to about 3.0 mm), it may also be advantageous to employ a stent delivery system sized at between about 0.022 to about 0.025 inch in diameter. Such a system can be used with catheters compatible with 0.022 inch diameter guidewires.


While such a system may not be suitable for reaching the very smallest vessels, in reaching the larger of the small vessels (i.e., those having a diameter of about 2.5 mm or larger), even this variation of the invention is quite advantageous in comparison to known systems. By way of comparison, the smallest known over-the-guidewire delivery systems are the Micro-Driver™ and Pixel™ systems by Guidant. These are adapted to treat vessels between 2 and 2.75 mm, the latter system having a crossing profile of 0.036 inches (0.91 mm). A system described in U.S. Patent Publication No. 2002/0147491 for treating small vessels is purported to be capable of being made as small as 0.026 inch (0.66 mm) in diameter.


With respect to such systems, however, it must be appreciated that a further decrease in stent size may be practically impossible in view of materials limitations and functional parameters of the stent. Instead, the present invention offers a different paradigm for delivery devices and stents that are scalable to the sizes noted herein.


By virtue of the approaches taught herein, it is feasible to design system diameters to match (or at least nearly match) common guidewire size diameters (i.e., 0.014, 0.018 and 0.022 inch) for small vessel delivery applications. As noted above, doing so facilitates use with compatible catheters and opens the possibility for methodology employing the same as elaborated upon below and in the above-referenced “Balloon Catheter Lumen Based Stent Delivery Systems” patent application.


Of further note, it may be desired to design a variation of the subject system for use in deploying stents in larger, peripheral vessels, biliary ducts or other hollow body organs. Such applications involve a stent being emplaced in a region having a diameter from about 3.5 to about 13 mm (0.5 inch). In this regard, the scalability of the present system, again, allows for creating a system adapted for such use that is designed around a common wire size. Namely, a 0.035 to 0.039 inch (3 FR) diameter crossing profile system is advantageously provided in which the stent expands (unconstrained) to a size between about roughly 0.5 mm and about 1.0 mm greater than the vessel or hollow body organ to be treated. Sufficient stent expansion is easily achieved with the exemplary stent pattern shown in FIG. 2.


Again, as a matter of comparison, the smallest delivery systems known to applicants for stent delivery in treating such larger-diameter vessels or biliary ducts is a 6 FR system (nominal 0.084 inch outer diameter), which is suited for use in an 8 FR guiding catheter. Thus, even in the larger sizes, the present invention affords opportunities not heretofore possible in achieving delivery systems in the size range of a commonly used guidewire, with the concomitant advantages discussed herein.


Several known stent delivery systems are compatible with (i.e., may be delivered over) common-sized guides wires ranging from 0.014 inch to 0.035 inch (0.89 mm). Yet, none of the delivery systems are themselves known to be so-sized.


As for the manner of using the inventive system as optionally configured, FIGS. 3A-3L illustrate an exemplary angioplasty procedure. Still, the delivery systems and stents or implants described herein may be used otherwise—especially as specifically referenced herein.


Turning to FIG. 3A, it shows a coronary artery 30 that is partially or totally occluded by plaque at a treatment site/lesion 32. Into this vessel, a guidewire 40 is passed distal to the treatment site. In FIG. 3B, a balloon catheter 42 with a balloon tip 44 is passed over the guidewire, aligning the balloon portion with the lesion (the balloon catheter shaft proximal to the balloon is shown in cross section with guidewire 40 therein).


As illustrated in FIG. 3C, balloon 44 is expanded (dilatated or dilated) in performing an angioplasty procedure, opening the vessel in the region of lesion 32. The balloon expansion may be regarded as “predilatation” in the sense that it will be followed by stent placement (and optionally) a “postdilataton” balloon expansion procedure.


Next, the balloon is at least partially deflated and passed forward, beyond the dilate segment 32′ as shown in FIG. 3D. At this point, guidewire 40 is removed as illustrated in FIG. 3E. It is exchanged for a delivery guide member 50 carrying stent 52 as further described below. This exchange is illustrated in FIGS. 3E and 3F.


However, it should be appreciated that such an exchange need not occur. Rather, the original guidewire device inside the balloon catheter (or any other catheter used) may be that of item 50, instead of the standard guidewire 40 shown in FIG. 3A. Thus, the steps depicted in FIGS. 3E and 3F (hence, the figures also) may be omitted. In addition, there may be no use in performing the step in FIG. 3D of advancing the balloon catheter past the lesion, since such placement is merely for the purpose of avoiding disturbing the site of the lesion by moving a guidewire past the same.



FIG. 3G illustrates the next act in either case. Particularly, the balloon catheter is withdrawn so that its distal end 46 clears the lesion. Preferably, delivery guide 50 is held stationary, in a stable position. After the balloon is pulled back, so is delivery device 50, positioning stent 52 where desired. Note, however, that simultaneous retraction may be undertaken, combining the acts depicted in FIGS. 3G and 3H. Whatever the case, it should also be appreciated that the coordinated movement will typically be achieved by virtue of skilled manipulation by a doctor viewing one or more radiopaque features associated with the stent or delivery system under medical imaging.


Once placement of the stent across from dilated segment 32′ is accomplished, stent deployment commences. The manner of deployment is elaborated upon below. Upon deployment, stent 52 assumes an at least partially expanded shape in apposition to the compressed plaque as shown in FIG. 3I. Next, the aforementioned postdilatation may be effected as shown in FIG. 3J by positioning balloon 44 within stent 52 and expanding both. This procedure may further expand the stent, pushing it into adjacent plaque—helping to secure each.


Naturally, the balloon need not be reintroduced for postdilatation, but it may be preferred. Regardless, once the delivery device 50 and balloon catheter 42 are withdrawn as in FIG. 3K, the angioplasty and stenting procedure at the lesion in vessel 30 is complete. FIG. 3L shows a detailed view of the emplaced stent and the desired resultant product in the form of a supported, open vessel.


In the above description, a 300 cm extendable delivery system is envisioned. Alternatively, the system can be 190 cm to accommodate a rapid exchange of monorail type of balloon catheter as is commonly known in the art. Of course, other approaches may be employed as well.


Furthermore, other endpoints may be desired such as implanting an anchoring stent in a hollow tubular body organ, closing off an aneurysm, delivering a plurality of stents, etc. In performing any of a variety of these or other procedures, suitable modification will be made in the subject methodology. The procedure shown is depicted merely because it illustrates a preferred mode of practicing the subject invention, despite its potential for broader applicability.


A more detailed overview of the subject delivery systems is provided in FIG. 4 Here, a delivery system 200 is shown along with a stent 202 held in a collapsed configuration upon the delivery guide member. A restraint 204 is provided over and around the stent. The restraint may fully surround the stent or only subtend a partial circumference of the stent, it may be split, splittable, comprise a plurality of member or be otherwise provided around the stent to hold or restrain it in a collapsed profile.


Regarding the overall delivery guide, however, it preferably comprises an atraumatic distal tip 206 of one variety or another. On the other end of the delivery device, a custom handle 208 is preferably provided.


The handle shown is adapted for rotable actuation by holding body 210, and turning wheel 212. It may include a lock 214. Furthermore, a removable interface member 216 facilitates taking the handle off of the delivery system proximal end 218. The interface will be lockable with respect to the body and preferably includes internal features for disengaging the handle from the delivery guide. Once accomplished, it will be possible to attach or “Doc” a secondary length of wire 220 on the delivery system proximal end, allowing the combination to serve as an “exchange length” guidewire, thereby facilitating changing-out the balloon catheter or performing another procedure. Alternatively, the wire may be an exchange-length wire.



FIG. 4 also shows packaging 250 containing at least one coiled-up delivery systems 200. When a plurality of such systems are provided (in one package or by way of a number of packages held in stock), they are typically configured in support of a methodology where an appropriate one is picked to reach a target site and deploy a stent without unintended axial movement of the same as per the methodology of the “Sliding Restraint Stent Delivery Systems” patent application referenced above. Thus, the packaging may serve the purpose of providing a kit or panel of differently configured delivery devices. In the alternative, the packaging may be configured as a tray kit for a single one of the delivery systems.


Either way, packaging may include one or more of an outer box 252 and one or more inner trays 254, 256 with peel-away coverings as is customary in packaging of disposable products provided for operating room use. Naturally, instructions for use can be provided therein. Such instructions may be printed product or be provided in connection with another readable (including computer-readable) medium. The instructions may include provision for basic operation of the subject devices and/or the selection methodology.


Regarding the specifics of the restraint employed in the delivery device, it preferably is one that does not have a section that increases in size during, or after, deployment of the stent. They are such that restraint diameter remains constant or actually decreases in diameter upon withdrawal from the stent and release of the same.


Regarding the first variation shown in FIGS. 5A-5C, FIGS. 5A and 5B show sub-assemblies, whereas the parts are combined in FIG. 5C. In FIG. 5A, a distal end 300 of the delivery device 200 is shown in partial cross-section. It includes an extension wire 302 attached/connected to a hypotube section 304. The hypotube extends proximally (to the left) and serves as the “sleeve” referred to above. For a “one-sided” system as further detailed in FIGS. 5B and 5C, the extension member 302 is offset within the tubing 304. This relation of elements is most clearly shown in Section A-A, showing a pass-through opening (“PT”) between the extension 302 and sleeve 304. It is in this manner, that this variation of the invention achieves the cross-over of its active members from the outer diameter of the device to the interior of the sleeve.


Distal of the connection “C” between members 302 and 304, a shoulder section may be ground into the wire or a separate ring 306 may be attached thereto to provide a stop surface 308 for abutting the stent to be delivered. Moving toward the distal tip 310, the system may be tapered as shown. The length of the extension over which the restraint rides is variable as is the restraint. The taper may be desired for increased distal flexibility.


The overall length of the system from a distal tip (possibly incorporating an atraumatic tip, to the base of any actuation device provided may be around 135 cm (53 inch) to 200 cm (79 inch) or more preferably between 180 cm (71 inch) and 190 cm (75 inch). Overall longer or shorter system lengths are also contemplated. The length of the extension 302 and stent-overlying restraint/connector is variable. The length of the extension section may be between about 10 cm to 15 cm, about 15 cm to about 25 cm or up to 30 cm or longer as possibly influenced or dictated by system flexibility requirements.


Returning, however, to the specific device configuration shown in FIG. 5A, it may be desired to create a flat section 312 for clearance purposes where the proximal end 314 of the extension member and distal end 316 of the sleeve overlap. To increase system compliance at this intersection where connection C is made, it may be desired to relieve or create an angled section 318 at the distal end of the hypotubing. To encourage even navigation performance characteristics, the extension wire will return to round as shown in Section B-B distal of the intersection.



FIG. 5B shows the remaining elements for the distal portion 300 of this variation of the delivery device. Specifically, an inner wire 320 (pictured in this case as a corewire providing column strength to the system and aiding in its noted desired functional characteristics in terms—such as in terms of torqueability and directability to a target site), a restraint 322 and connector 324 for attachment of the pieces as shown. The connector includes a bridge section 326 that crosses from the outside diameter “D” of the device to inside, traversing pass-through PT. Bonding sections 328, 330 are provided, preferably for gluing to the restraint and a distal end 332 of the inner wire 320.


Of course, the restraint and bridge section may be provided integrally (in which case the bridge may be connected directly to the inner member—or by differently configured connector piece). Otherwise, they may be made of different materials. For example, the connector may comprise stainless steel or Nitinol (just as other members of the delivery guide) and the restraint a polymeric material. A polymeric restraint (such as polyimide or PET may be desired since it is readily obtained in very thin-wall tubing—down to 0.00025 inch).


In FIG. 5C, the various components discussed above are assembled with the distal portion shown in partial cross-section as in FIG. 5A. Section C-C shows the manner in which bridge section 326 passes by extension section 302 within the device. To provide a low-profile device, the bridge section and extension run substantially in parallel. Indeed, all of the cross-sections show the close-packed arrangement of elements. Further, a stent 202 is shown in a collapsed configuration within the restraint.


Overall, the system has a diameter (“D”) dictating its crossing profile. To actuate the device, inner/core member 320 is withdrawn causing the restraint to slide off of the stent without the diameter D to increase as the clearance gap (“G”) between the restraint and sleeve is closed.


Note, however, that it may be the case that no open gap G is provided. This may be accomplished by extending the sleeve over the connector as indicated by dashed lines in FIG. 5C over the gap. Indeed, this “hidden” bridge or connector variation of the invention may be desirable in order to help prevent system kinking or pushing the restraint forward after retraction (such as is in an abortive stent delivery procedure) or just generally protecting any bridge section(s).


As noted above, the sleeve may be extended by another piece of material connected thereto. Advantageously, it could be a thin-walled polymeric tube. Alternatively, the “extension” may be provided in a relative sense by moving the connection point between the sleeve and the extension wire proximally within the sleeve. In either case, the additional sleeve length and relative positioning of elements is indicated by the addition of the phantom line structure in FIG. 5C.


Another variation of the invention is shown in FIGS. 6A-6C. This is a two-sided device. By two-sided, what is meant is that two bridge sections 326 are provided in the connector 324 or otherwise. To accommodate these members, the connection is provided by a spanning or web member 340. It can be press-fit or otherwise attached or connected to opposing wall portions 342 of sleeve 304. Thus assembled, two pass-throughs are provided, one for each bridge section crossing over into the core wire lumen of the device. Section C-C in FIG. 6C provides a view of the components so-arranged.


Yet, except for the symmetry that such an approach provides over that of the one-sided approach (and concomitant advantages in terms of consistency in flexibility and distribution of loads, for example), the system is much like that shown in FIGS. 5A-5C. Accordingly, for the sake of brevity further discussion is omitted. Still, it is noted that advantages of a two-sided system over a one-sided system in terms of dynamic performance may prove to be important—especially in more demanding applications of the delivery device where a one-sided system might be more prone to kinking or biased behavior.



FIG. 7 shows further optional aspects of the invention. Specifically, it illustrates a diameter-adaptive restraint as discussed above. Alternate sections A-A picture two-sided and three-sided connection approaches in line with those discussed above. Regarding the three-sided approach, this will offer a further improved quality of balanced performance.


In any case, the side sectional view in FIG. 7 show a distal portion 400 of delivery device 200. For ease of illustration, only half of the structure is shown. In this view, corewire 402 is slidingly received by a sleeve 404. A stent 406 is held in a collapsed configuration by a restraint 408 over an extension wire/member 410 connected to sleeve 404. A shoulder section 412 is provided on the extension. A distal surface 414 defined by the shoulder provides a stent abutment feature.


Connection options between the extension member and the sleeve are shown in sections D-D. The sections show the connection sections “C” as well as the manner in which bridge sections 416 pass by the same.


Note, further that the restraint in this variation of the delivery device may change diameter from a diameter external to the stent to a diameter internal to the delivery device. Yet, this need not be the case. However, it provides a highly space-efficient system, in which the length of the restraint and any bridge sections can be minimized.


Furthermore, it should be noted that the device may be configured such that bridge sections are progressively formed by cutting the restraint apart as it is drawn into the sleeve. Blade or wedge portion 418 can assist in such action. Alternatively, the restraint may be scored, perforated or otherwise made splittable so that simply being pulled into openings across the connection C separates the restraint into bridge sections.


Still further, it is contemplated that the restraint may be pre-split. An example of such a case is shown in FIGS. 8A and 8B. Here, restraint portion 500 comprises a plurality of bands or ribbons wound about the stent. Bridge sections 416 adjoin the restraint portion(s). The manner in which each band 420 wraps around and holds the stent 406 in a collapsed profile is best illustrated in FIG. 8A.



FIG. 8B shows the manner in which the band/straps 420 may be configured as a diameter adaptive restraint. In this regard, a section will pass under and into sleeve past its connection with extension wire 410 (again, optionally terminating in an atraumatic tip). Path “A” diagrammatically illustrates this action. Alternatively, at least the sleeve 404, but likely also the core member 402 can be expanded as indicated, such that the restraint slides directly into the same. Yet another option to facilitate the action indicated by path B is to provide a sleeve with a reduced wall thickness extension (such as in the form of thin-walled polymeric tubing) or by providing hypotubing with a thinned down distal end—such as by swaging, grinding or another manufacturing technique.



FIG. 9 shows a variation of the invention related to that shown in FIG. 5C. This variation of the invention employs an extension from the core wire as a bridge section 326′. Both of the extension member 302 and core wire may be undercut or tapered as in complimentary sections 328 (or otherwise) to facilitate uniform flexibility and/or reduce system stress-raisers. In addition, sleeve 304 includes an extension 342 thereto connected at another tapered section 340. The length of this taper (as with any other shown) may be varied, for example, to provide a uniform performance transition between members. Extension 342 is advantageously made of a lower modulus and/or thinner material than sleeve 304 (such as plastic vs. metal) to promote flexibility of the distal end of the device. As with the sleeve itself, the length or terminal placement of the sleeve extension 344 may be varied as indicated by the broken/phantom line.



FIG. 10 shows a variation of the optional configuration noted with respect to FIG. 6C above. More specifically, sleeve 304 extends over bridge sections 326. In addition connector section 328 is lengthened. Such a configuration may be desired in order to provide an overall longer or more flexible distal end.



FIGS. 11A and 11B are cross-sectional side views of distal portions of another variation of the present invention. In FIG. 11A, a more proximal portion of the distal end of the device is shown. This variation, closely resembles the variation in FIG. 9 except for that it includes a coil 350 surrounding both the bridge segment/core wire extension 326′ and extension member 302. The coil may be ribbon wound in a helical fashion, tubing laser or EDM cut into a spiral, round wire, etc. Such a form-factor advantageously decreases profile. Still, the coil may comprise round or square wire wound into a coil. The coil will generally be metallic (e.g., stainless steel, titanium alloy, NiTi, platinum, etc.). At smaller sizes, metal may be required to offer sufficient resistance from cutting by bridge member 326′ and to secure it from separating from extension wire 302 when actuated along a tight curve.


An important aspect of the invention that is well illustrated in FIG. 11A is the manner in which bridge segment 326′ parallels extension member 302 in order to conserve space. This arrangement offers particular elegance in component size miniaturization. Manufacturability is also benefited in that sleeve 304 is quite open across from the connection between extension member 302 and sleeve 304 prior to insertion of the core wire 320 during assembly. This approach (indicated by the double arrow) allow for relative ease of access for soldering or otherwise connecting the pieces.


The coil may be secured at a proximal point or location “PC” to the extension member or sleeve. Then, by preloading the structure and securing it at a distal location “DC” to the restraint (optionally, by way of an intermediate band 328 shown in FIG. 11B) the system is preloaded to help in withdrawing the restraint from the stent when desired. In this manner, the coil may serve two purposes. For the preload application, it may be desirable to make the coil of a highly elastic or high strength material such as NiTi or Stainless Steel. However, other connection schemes are possible.



FIG. 11B also shows an optional stent blocker/marker 306, restraint 322 and stent 202 within a receiving zone over extension member 302. Additional moving markers may be provided, though none are shown. FIGS. 12A-12C are cross-sectional views of the variation of the invention shown in FIGS. 11A and 11B, taken along lines C-C, D-D and E-E, respectively. They the various components noted in the previous figures. In addition, they help illustrate the relative sizing of the parts as may be useful in optimizing system performance, particularly the manner in which bridge segment 326′ is flattened or coined relative to the main core wire body 320. Also worth noting is that each of the components fit within the same envelope. In other words, the coil member can be added to the system without increasing its overall diameter.



FIG. 13 is a cross-sectional side view of another variation of the present invention. As shown, the distal end 300 of the system is on the left. Again, various ones of the parts resemble those above. The greatest difference between the systems is observed in connection with the bridge member 326″. Here, the member is a hollow member shown in the form of a slotted tube. Slot 360 allows bridge tube to slide past the connection between the connection between extension member 302 and sleeve 304.


The sleeve optionally extends beyond this connection point “C” as shown. Such an approach offers a system less prone to contamination and potentially more stable in actuation. However, it may require a weld-type joint or an interlocking interface with a hole (not show) in sleeve. As above, cross-sectional views taken along various lines—in this case FIGS. 14A-14C taken along lines B-B, C-C and D-D, respectively—illustrate optional relationships between the constituent parts of this variation of the invention.



FIG. 15 is a cross-sectional side view of a distal end 300 of still another variation of the invention. As above, FIGS. 16A and 16B provide cross-sectional views at various points along the distal end 300 of the device, taken along lines B-B and C-C, respectively.


In the variation of the invention in FIGS. 15, 16A and 16B, the extension member comprises a wire section 302 upon which stent 202 is mounted, along with a tubular proximal section 302′. The tubular proximal sections surround bridge segment 326′ extending from core wire and crossing over to make a distal connection “DC” with restraint 322 by way of optional turn 364. The bent or turned-back section 362 offers a convenient means of spanning the space between the internally actuated core member 320 and the exterior restraint 322. A proximal connection “PC” may be a solder joint, a glue joint, a weld joint as may be the distal connection. In addition, the proximal connection may be an interference fit—or be avoided altogether by integrating the function of the proximal extension member into sleeve 304, by extending the sleeve and making a slot therein to allow traversal of turn 362 or another cross-over structure therethrough.


Extension member 302′ is shown as a tube with a slot 364 formed therein. The slot is shown covered by restraint 322, though this need not be the case. Indeed, this “tube” 302′ and tube 326″ may be configured otherwise. Either entity may be any sort of body including various oval, hex, square, etc. sections—either with a closed periphery at some location or slotted aling the entire length so as to define one-half, two-thirds of a tube or any of a C, U, V section. etc.


Regardless of all such optional constructions or alternative variations, in a generic sense, the delivery guide member body comprises or consists substantially of an inner member (possibly a core member in order to minimize size and maximize strength) set within a proximal tubular member or sleeve, with an extension member secured to or within the tubular member. The extension section carries the stent and preferably terminates in an atraumatic tip. A restraint is provided external to a collapsed stent, the restraint being actuated by the core member in an inside-out fashion, particularly by way of a bridging connection between the inner member and the restraint.


In regard to any such system, it is to be understood that conventional materials and techniques may be employed in the system construction. In this regard, it will often be desired to provide a lubricious coating or cover between moving components to reduce internal system friction.


In addition, it is to be understood that various radiopaque markers or features may be employed in the system to 1) locate stent position and length, 2) indicate device actuation and stent delivery and/or 3) locate the distal end of the delivery guide. As such, various platinum (or other radiopaque material) bands or other markers (such as tantalum plugs) may be variously incorporated into the system. Alternatively, or additionally, the stent stop or blocker member may be made of radiopaque material. Especially where the stent employed may shorten somewhat upon deployment, it may also be desired to align radiopaque features with the expected location (relative to the body of the guide member) of the stent upon deployment. For example, it may be desired to incorporate radiopaque features into the restraint and/or bridge or connector sections so that the deployment motion of the device is visible under fluoroscopy. Exemplary markers that may be of use are shown at a proximal end of the stent in FIG. 4 as elements A and A′—on the delivery guide body and restraint, respectively—and at a distal end of the stent on the restraint as element B.


Though the invention has been described in reference to several examples, optionally incorporating various features, the invention is not to be limited to that which is described or indicated as contemplated with respect to each embodiment or variation of the invention. The breadth of the present invention is to be limited only by the literal or equitable scope of the following claims. That being said,

Claims
  • 1. A stent delivery system comprising: a self-expanding stent;an inner wire;an outer sleeve, the inner wire slidingly received within the sleeve;an extension member having a proximal end attached to a distal portion of the outer sleeve;a restraint holding the stent collapsed over a distal wire portion of the extension member; anda bridge segment connecting a proximal end of the restraint to a distal end of the inner wire so that proximal retraction of the inner wire relative to the outer sleeve retracts the restraint to release the stent.
  • 2. The system of claim 1, wherein the inner wire comprises a corewire.
  • 3. The system of claim 1, wherein a proximal portion of the delivery guide consists essentially of the sleeve and the inner wire, wherein the inner wire is a core wire.
  • 4. The system of claim 1, wherein the bridge segment is an integral extension of the inner wire.
  • 5. The system of claim 1, wherein the bridge segment comprises a member attached to the inner wire.
  • 6. The system of claim 1, wherein the bridge segment has a flattened shape.
  • 7. The system of claim 1, wherein the extension member consists essentially of a wire.
  • 8. The system of claim 1, further comprising a coil surrounding at least a portion of each of the extension member and the bridge segment.
  • 9. The system of claim 8, wherein the coil is secured to each of the sleeve and restraint.
  • 10. The system of claim 1, wherein the extension member comprises a hollow body proximal to the distal wire portion of the extension member.
  • 11. The system of claim 10, wherein the hollow body comprises a tube.
  • 12. The system of claim 11, wherein the tube is slotted at a distal end.
  • 13. The system of claim 1, wherein the connection between the extension member and the sleeve is proximal to a distal end of the sleeve.
  • 14. The system of claim 1 or 13, wherein the sleeve overlays the bridge segment.
  • 15. The system of claim 1, wherein the bridge segment comprises a hollow body.
  • 16. The system of claim 15, wherein the hollow body comprises a tube.
  • 17. The system of claim 1, wherein only one bridge segment is provided.
  • 18. The system of claim 1, wherein a plurality of bridge segments are provided.
  • 19. The system of claim 1, wherein a stent stop surface is provided to abut a proximal end of the stent.
  • 20. The system of claim 1, wherein the connection between the extension wire and the sleeve is symmetrical about an axis along the tubular body.
  • 21. The system of claim 1, 3, or 8, wherein the system comprises an atraumatic tip.
CROSS-REFERENCE TO RELATED APPLICATIONS

This is a Continuation-In-Part of co-pending U.S. patent application Ser. No. 10/792,679 filed Mar. 2, 2004, which application is incorporated by reference herein in its entirety.

US Referenced Citations (348)
Number Name Date Kind
4503569 Dotter Mar 1985 A
4512338 Balko et al. Apr 1985 A
4553545 Maass et al. Nov 1985 A
4562596 Kornberg Jan 1986 A
4580568 Gianturco Apr 1986 A
4655771 Wallsten Apr 1987 A
4665918 Garza et al. May 1987 A
4732152 Wallsten et al. Mar 1988 A
4733665 Palmaz Mar 1988 A
4762128 Rosenbluth Aug 1988 A
4768507 Fischell et al. Sep 1988 A
4771773 Kropf Sep 1988 A
4776337 Palmaz Oct 1988 A
4830003 Wolff et al. May 1989 A
4848343 Wallsten et al. Jul 1989 A
4875480 Imbert Oct 1989 A
4878906 Lindemann et al. Nov 1989 A
4893623 Rosenbluth Jan 1990 A
4913141 Hillstead Apr 1990 A
4950227 Savin et al. Aug 1990 A
4954126 Wallsten Sep 1990 A
4969890 Sugita et al. Nov 1990 A
4990151 Wallsten Feb 1991 A
4990155 Wilkoff Feb 1991 A
4998539 Delsanti Mar 1991 A
5019085 Hillstead May 1991 A
5019090 Pinchuk May 1991 A
5026377 Burton et al. Jun 1991 A
5035706 Giantureo et al. Jul 1991 A
5061275 Wallsten et al. Oct 1991 A
5064435 Porter Nov 1991 A
5067957 Jervis Nov 1991 A
5071407 Termin et al. Dec 1991 A
5089006 Stiles Feb 1992 A
5092877 Pinchuk Mar 1992 A
5102417 Palmaz Apr 1992 A
5108407 Geremia et al. Apr 1992 A
5108416 Ryan et al. Apr 1992 A
5122136 Guglielmi et al. Jun 1992 A
5147370 McNamara et al. Sep 1992 A
5158548 Lau et al. Oct 1992 A
5180367 Kontos et al. Jan 1993 A
5192297 Hull Mar 1993 A
5201757 Heyn et al. Apr 1993 A
5221261 Termin et al. Jun 1993 A
5242399 Lau et al. Sep 1993 A
5242452 Inoue Sep 1993 A
5246445 Yachia et al. Sep 1993 A
5263964 Purdy Nov 1993 A
5266073 Wall Nov 1993 A
5290305 Inoue Mar 1994 A
5306294 Winston et al. Apr 1994 A
5320635 Smith Jun 1994 A
5334210 Gianturco Aug 1994 A
5354295 Guglielmi et al. Oct 1994 A
5360401 Turnland Nov 1994 A
5372600 Beyar et al. Dec 1994 A
5382259 Phelps et al. Jan 1995 A
5407432 Solar Apr 1995 A
5415664 Pinchuk May 1995 A
5423829 Pham et al. Jun 1995 A
5433723 Lindenberg et al. Jul 1995 A
5443477 Marin et al. Aug 1995 A
5445646 Euteneuer et al. Aug 1995 A
5476505 Limon Dec 1995 A
5484444 Braunschweiler et al. Jan 1996 A
5486195 Myers et al. Jan 1996 A
5507771 Gianturco Apr 1996 A
5522836 Palermo Jun 1996 A
5522883 Slater et al. Jun 1996 A
5534007 St. Germain et al. Jul 1996 A
5540680 Guglielmi et al. Jul 1996 A
5554181 Das Sep 1996 A
5569245 Guglielmi et al. Oct 1996 A
5571135 Fraser et al. Nov 1996 A
5578074 Mirigian Nov 1996 A
5591196 Marin et al. Jan 1997 A
5601600 Ton Feb 1997 A
5618300 Marin et al. Apr 1997 A
5643254 Scheldrup et al. Jul 1997 A
5653748 Strecker Aug 1997 A
5683451 Lenker et al. Nov 1997 A
5690643 Wijay Nov 1997 A
5690644 Yurek et al. Nov 1997 A
5702364 Euteneuer et al. Dec 1997 A
5702418 Ravenscroft Dec 1997 A
5725551 Myers et al. Mar 1998 A
5733267 Del Toro Mar 1998 A
5733325 Robinson et al. Mar 1998 A
5772609 Nguyen et al. Jun 1998 A
5772668 Summers et al. Jun 1998 A
5772669 Vrba Jun 1998 A
5776141 Klein et al. Jul 1998 A
5776142 Gunderson Jul 1998 A
5782838 Beyar et al. Jul 1998 A
5788707 Del Toro et al. Aug 1998 A
5797857 Obitsu Aug 1998 A
5797952 Klein Aug 1998 A
5800455 Palermo et al. Sep 1998 A
5800517 Anderson et al. Sep 1998 A
5807398 Shaknovich Sep 1998 A
5810837 Hofmann et al. Sep 1998 A
5817101 Fiedler Oct 1998 A
5824041 Lenker et al. Oct 1998 A
5824058 Ravenscroft et al. Oct 1998 A
5843090 Schuetz Dec 1998 A
5851206 Guglielmi et al. Dec 1998 A
5855578 Guglielmi et al. Jan 1999 A
5873907 Frantzen Feb 1999 A
5891128 Gia et al. Apr 1999 A
5919187 Guglielmi et al. Jul 1999 A
5919204 Lukic et al. Jul 1999 A
5919225 Lau et al. Jul 1999 A
5920975 Morales Jul 1999 A
5941888 Wallace et al. Aug 1999 A
5944726 Blaeser et al. Aug 1999 A
5957930 Vrba Sep 1999 A
5968052 Sullivan, III et al. Oct 1999 A
5980485 Grantz et al. Nov 1999 A
5980514 Kupiecki et al. Nov 1999 A
5980530 Willard et al. Nov 1999 A
5984929 Bashiri et al. Nov 1999 A
5989242 Saadat et al. Nov 1999 A
5989280 Euteneuer et al. Nov 1999 A
6004328 Solar Dec 1999 A
6015429 Lau et al. Jan 2000 A
6019737 Murata Feb 2000 A
6019779 Thorud et al. Feb 2000 A
6027516 Kolobow et al. Feb 2000 A
6027520 Tsugita et al. Feb 2000 A
6042588 Munsinger et al. Mar 2000 A
6042589 Marianne Mar 2000 A
6042605 Martin et al. Mar 2000 A
6048360 Khosravi et al. Apr 2000 A
6056759 Fiedler May 2000 A
6059779 Mills May 2000 A
6059813 Vrba et al. May 2000 A
6063101 Jacobsen et al. May 2000 A
6063104 Villar et al. May 2000 A
6068634 Lorentzen Cornelius et al. May 2000 A
6068644 Lulo et al. May 2000 A
6071286 Mawad Jun 2000 A
6077297 Robinson et al. Jun 2000 A
6093194 Mikus et al. Jul 2000 A
6096034 Kupiecki et al. Aug 2000 A
6096045 Del Toro et al. Aug 2000 A
6102942 Ahari Aug 2000 A
6113608 Monroe et al. Sep 2000 A
6117140 Munsinger Sep 2000 A
6120522 Vrba et al. Sep 2000 A
6123714 Gia et al. Sep 2000 A
6123720 Anderson et al. Sep 2000 A
6126685 Lenker et al. Oct 2000 A
6139524 Killion Oct 2000 A
6139564 Teoh Oct 2000 A
6156061 Wallace et al. Dec 2000 A
6161029 Spreigl et al. Dec 2000 A
6165178 Bashiri et al. Dec 2000 A
6168592 Kupiecki et al. Jan 2001 B1
6168616 Brown, III Jan 2001 B1
6168618 Frantzen Jan 2001 B1
6174327 Mertens et al. Jan 2001 B1
6183481 Lee et al. Feb 2001 B1
6183505 Mohn, Jr. et al. Feb 2001 B1
6193708 Ken et al. Feb 2001 B1
6200305 Berthiaume et al. Mar 2001 B1
6203550 Olson Mar 2001 B1
6206888 Bicek et al. Mar 2001 B1
6214036 Letendre et al. Apr 2001 B1
6221081 Mikus et al. Apr 2001 B1
6228110 Munsinger May 2001 B1
6238430 Klumb et al. May 2001 B1
6241758 Cox Jun 2001 B1
6245097 Inoue Jun 2001 B1
6248122 Klumb et al. Jun 2001 B1
6254609 Vrba et al. Jul 2001 B1
6254611 Vrba Jul 2001 B1
6254628 Wallace et al. Jul 2001 B1
6264683 Stack et al. Jul 2001 B1
6267783 Letendre et al. Jul 2001 B1
6270504 Lorentzen Cornelius et al. Aug 2001 B1
6273881 Kiemeneij Aug 2001 B1
6280465 Cryer Aug 2001 B1
6287331 Heath Sep 2001 B1
6302893 Limon et al. Oct 2001 B1
6306141 Jervis Oct 2001 B1
6342066 Toro et al. Jan 2002 B1
6344041 Kupiecki et al. Feb 2002 B1
6346118 Baker et al. Feb 2002 B1
6350277 Kocur Feb 2002 B1
6350278 Lenker et al. Feb 2002 B1
6361637 Martin et al. Mar 2002 B2
6368344 Fitz Apr 2002 B1
6371962 Ellis et al. Apr 2002 B1
6375660 Fischell et al. Apr 2002 B1
6379365 Diaz Apr 2002 B1
6380457 Yurek et al. Apr 2002 B1
6383174 Eder May 2002 B1
6387118 Hanson May 2002 B1
6391050 Broome May 2002 B1
6391051 Sullivan, III et al. May 2002 B2
6395017 Dwyer et al. May 2002 B1
6409750 Hyodoh et al. Jun 2002 B1
6409752 Boatman et al. Jun 2002 B1
6413269 Bui et al. Jul 2002 B1
6416536 Yee Jul 2002 B1
6416545 Mikus et al. Jul 2002 B1
6423090 Hancock Jul 2002 B1
6425898 Wilson et al. Jul 2002 B1
6425914 Wallace et al. Jul 2002 B1
6425915 Khosravi et al. Jul 2002 B1
6428489 Jacobsen et al. Aug 2002 B1
6428566 Holt Aug 2002 B1
6432080 Pederson, Jr. et al. Aug 2002 B2
6432129 DiCaprio Aug 2002 B2
6447540 Fontaine et al. Sep 2002 B1
6448700 Gupta et al. Sep 2002 B1
6451025 Jervis Sep 2002 B1
6454795 Chuter Sep 2002 B1
6458092 Gambale et al. Oct 2002 B1
6468266 Bashiri et al. Oct 2002 B1
6468301 Amplatz et al. Oct 2002 B1
6482227 Solovay Nov 2002 B1
6485515 Strecker Nov 2002 B2
6488700 Klumb et al. Dec 2002 B2
6517548 Lorentzen Cornelius et al. Feb 2003 B2
6517569 Mikus et al. Feb 2003 B2
6520986 Martin et al. Feb 2003 B2
6530947 Euteneuer et al. Mar 2003 B1
6533805 Jervis Mar 2003 B1
6533807 Wolinsky et al. Mar 2003 B2
6537295 Petersen Mar 2003 B2
6558415 Thompson May 2003 B2
6562063 Euteneuer et al. May 2003 B1
6562064 deBeer May 2003 B1
6579297 Bicek et al. Jun 2003 B2
6579308 Jansen et al. Jun 2003 B1
6582460 Cryer Jun 2003 B1
6602226 Smith et al. Aug 2003 B1
6602272 Boylan et al. Aug 2003 B2
6607539 Hayashi et al. Aug 2003 B1
6607551 Sullivan et al. Aug 2003 B1
6613079 Wolinsky et al. Sep 2003 B1
6620152 Guglielmi Sep 2003 B2
6623518 Thompson et al. Sep 2003 B2
6626938 Butaric et al. Sep 2003 B1
6629981 Bui et al. Oct 2003 B2
6645237 Klumb et al. Nov 2003 B2
6645238 Smith Nov 2003 B2
6656212 Ravenscroft et al. Dec 2003 B2
6660031 Tran et al. Dec 2003 B2
6660032 Klumb et al. Dec 2003 B2
6663660 Dusbabek et al. Dec 2003 B2
6666881 Richter et al. Dec 2003 B1
6669719 Wallace et al. Dec 2003 B2
6676666 Vrba et al. Jan 2004 B2
6679910 Granada Jan 2004 B1
6689120 Gerdts Feb 2004 B1
6692521 Pinchasik Feb 2004 B2
6699274 Stinson Mar 2004 B2
6702843 Brown et al. Mar 2004 B1
6709425 Gambale et al. Mar 2004 B2
6716238 Elliott Apr 2004 B2
6726714 DiCaprio et al. Apr 2004 B2
6733519 Lashinski et al. May 2004 B2
6736839 Cummings May 2004 B2
6802858 Gambale et al. Oct 2004 B2
6814746 Thompson et al. Nov 2004 B2
6818014 Brown et al. Nov 2004 B2
6830575 Stenzel et al. Dec 2004 B2
6833003 Jones et al. Dec 2004 B2
6858034 Hijlkema et al. Feb 2005 B1
6860899 Rivelli, Jr. Mar 2005 B1
6936058 Forde et al. Aug 2005 B2
6936065 Khan et al. Aug 2005 B2
6989024 Hebert et al. Jan 2006 B2
7011673 Fischell et al. Mar 2006 B2
7074236 Rabkin et al. Jul 2006 B2
7172620 Gilson Feb 2007 B2
7300460 Levine et al. Nov 2007 B2
20010034548 Vrba et al. Oct 2001 A1
20010047185 Satz Nov 2001 A1
20010049547 Moore Dec 2001 A1
20010049550 Martin et al. Dec 2001 A1
20020002397 Martin et al. Jan 2002 A1
20020032431 Kiemeneij Mar 2002 A1
20020035393 Lashinski et al. Mar 2002 A1
20020040236 Lau et al. Apr 2002 A1
20020045928 Boekstegers Apr 2002 A1
20020045930 Burg et al. Apr 2002 A1
20020049490 Pollock et al. Apr 2002 A1
20020068966 Holman et al. Jun 2002 A1
20020072729 Hoste et al. Jun 2002 A1
20020095147 Shadduck Jul 2002 A1
20020095168 Griego et al. Jul 2002 A1
20020099433 Fischell et al. Jul 2002 A1
20020120322 Thompson et al. Aug 2002 A1
20020120323 Thompson et al. Aug 2002 A1
20020120324 Holman et al. Aug 2002 A1
20020138129 Armstrong et al. Sep 2002 A1
20020147491 Khan et al. Oct 2002 A1
20020161342 Rivelli, Jr. et al. Oct 2002 A1
20020169494 Mertens et al. Nov 2002 A1
20020188341 Elliott et al. Dec 2002 A1
20030014103 Inoue Jan 2003 A1
20030018319 Kiemeneij Jan 2003 A1
20030036768 Hutchins et al. Feb 2003 A1
20030040771 Hyodoh et al. Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030055377 Sirhan et al. Mar 2003 A1
20030065375 Eskuri Apr 2003 A1
20030069521 Reynolds et al. Apr 2003 A1
20030105508 Johnson et al. Jun 2003 A1
20030135266 Chew et al. Jul 2003 A1
20030149467 Linder et al. Aug 2003 A1
20030163156 Hebert et al. Aug 2003 A1
20030163189 Thompson et al. Aug 2003 A1
20040010265 Karpiel Jan 2004 A1
20040049547 Matthews et al. Mar 2004 A1
20040093063 Wright et al. May 2004 A1
20040127912 Rabkin et al. Jul 2004 A1
20040193178 Nikolchev Sep 2004 A1
20040193179 Nikolchev Sep 2004 A1
20040193246 Ferrera Sep 2004 A1
20040220585 Nikolchev Nov 2004 A1
20040260377 Flomenblit et al. Dec 2004 A1
20050080430 Wright, Jr. et al. Apr 2005 A1
20050096724 Stenzel et al. May 2005 A1
20050209670 George et al. Sep 2005 A1
20050209671 Ton et al. Sep 2005 A1
20050209672 George Sep 2005 A1
20060111771 Ton et al. May 2006 A1
20060136037 DeBeer et al. Jun 2006 A1
20060247661 Richards et al. Nov 2006 A1
20060270948 Viswanathan et al. Nov 2006 A1
20060271097 Ramzipoor et al. Nov 2006 A1
20060276886 George et al. Dec 2006 A1
20070027522 Chang et al. Feb 2007 A1
20070043419 Nikolchev et al. Feb 2007 A1
20070073379 Chang et al. Mar 2007 A1
20070100414 Licata et al. May 2007 A1
20070100415 Licata May 2007 A1
20070100416 Licata May 2007 A1
20070100417 Licata May 2007 A1
20070100418 Licata May 2007 A1
20080015541 Rosenbluth et al. Jan 2008 A1
20080071309 Mazzocchi et al. Mar 2008 A1
20080221666 Licata et al. Sep 2008 A1
Foreign Referenced Citations (13)
Number Date Country
4420142 Sep 1994 DE
0667 132 Aug 1995 EP
0747021 Nov 1996 EP
1 157 673 Nov 2001 EP
1518515 Mar 2005 EP
WO 9823241 Jun 1998 WO
WO 9904728 Feb 1999 WO
WO 0018330 Apr 2000 WO
WO 0178627 Oct 2001 WO
WO 03073963 Sep 2003 WO
WO 2004087006 Oct 2004 WO
WO 2005092241 Oct 2005 WO
WO 2005094727 Oct 2005 WO
Related Publications (1)
Number Date Country
20050209675 A1 Sep 2005 US
Continuation in Parts (1)
Number Date Country
Parent 10792679 Mar 2004 US
Child 10991721 US